Adalat: A Comprehensive Review
As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceu...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
1991
|
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge |
| Beschreibung: | 1 Online-Ressource (XV, 237 p. 77 illus., 21 illus. in color) |
| ISBN: | 9783642854989 |
| DOI: | 10.1007/978-3-642-85498-9 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046143842 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1991 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642854989 |9 978-3-642-85498-9 | ||
| 024 | 7 | |a 10.1007/978-3-642-85498-9 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-85498-9 | ||
| 035 | |a (OCoLC)1118999850 | ||
| 035 | |a (DE-599)BVBBV046143842 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 084 | |a VS 8100 |0 (DE-625)147711:253 |2 rvk | ||
| 084 | |a XI 4300 |0 (DE-625)153005:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Adalat |b A Comprehensive Review |c edited by P. R. Lichtlen, A. Reale |
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 1991 | |
| 300 | |a 1 Online-Ressource (XV, 237 p. 77 illus., 21 illus. in color) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 520 | |a As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Cardiology | |
| 650 | 0 | 7 | |a Nifedipin |0 (DE-588)4042297-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Geschichte |0 (DE-588)4020517-4 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Nifedipin |0 (DE-588)4042297-5 |D s |
| 689 | 0 | 1 | |a Geschichte |0 (DE-588)4020517-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Nifedipin |0 (DE-588)4042297-5 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Lichtlen, P. R. |4 edt | |
| 700 | 1 | |a Reale, A. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540540335 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642854996 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642855009 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-85498-9 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031524026 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-85498-9 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180478448631808 |
|---|---|
| any_adam_object | |
| author2 | Lichtlen, P. R. Reale, A. |
| author2_role | edt edt |
| author2_variant | p r l pr prl a r ar |
| author_facet | Lichtlen, P. R. Reale, A. |
| building | Verbundindex |
| bvnumber | BV046143842 |
| classification_rvk | VS 8100 XI 4300 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-85498-9 (OCoLC)1118999850 (DE-599)BVBBV046143842 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| doi_str_mv | 10.1007/978-3-642-85498-9 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03555nmm a2200565zc 4500</leader><controlfield tag="001">BV046143842</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1991 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642854989</subfield><subfield code="9">978-3-642-85498-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-85498-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-85498-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118999850</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046143842</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 8100</subfield><subfield code="0">(DE-625)147711:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4300</subfield><subfield code="0">(DE-625)153005:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adalat</subfield><subfield code="b">A Comprehensive Review</subfield><subfield code="c">edited by P. R. Lichtlen, A. Reale</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XV, 237 p. 77 illus., 21 illus. in color)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nifedipin</subfield><subfield code="0">(DE-588)4042297-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nifedipin</subfield><subfield code="0">(DE-588)4042297-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Nifedipin</subfield><subfield code="0">(DE-588)4042297-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lichtlen, P. R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reale, A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540540335</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642854996</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642855009</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-85498-9</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031524026</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-85498-9</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046143842 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:24Z |
| institution | BVB |
| isbn | 9783642854989 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031524026 |
| oclc_num | 1118999850 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XV, 237 p. 77 illus., 21 illus. in color) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| spelling | Adalat A Comprehensive Review edited by P. R. Lichtlen, A. Reale Berlin, Heidelberg Springer Berlin Heidelberg 1991 1 Online-Ressource (XV, 237 p. 77 illus., 21 illus. in color) txt rdacontent c rdamedia cr rdacarrier As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar macological revolution, which started out from whole animal models and progres sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge Cardiology Nifedipin (DE-588)4042297-5 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Geschichte (DE-588)4020517-4 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Nifedipin (DE-588)4042297-5 s Geschichte (DE-588)4020517-4 s DE-604 Pharmakotherapie (DE-588)4076066-2 s Lichtlen, P. R. edt Reale, A. edt Erscheint auch als Druck-Ausgabe 9783540540335 Erscheint auch als Druck-Ausgabe 9783642854996 Erscheint auch als Druck-Ausgabe 9783642855009 https://doi.org/10.1007/978-3-642-85498-9 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Adalat A Comprehensive Review Cardiology Nifedipin (DE-588)4042297-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Geschichte (DE-588)4020517-4 gnd |
| subject_GND | (DE-588)4042297-5 (DE-588)4076066-2 (DE-588)4020517-4 (DE-588)4143413-4 |
| title | Adalat A Comprehensive Review |
| title_auth | Adalat A Comprehensive Review |
| title_exact_search | Adalat A Comprehensive Review |
| title_full | Adalat A Comprehensive Review edited by P. R. Lichtlen, A. Reale |
| title_fullStr | Adalat A Comprehensive Review edited by P. R. Lichtlen, A. Reale |
| title_full_unstemmed | Adalat A Comprehensive Review edited by P. R. Lichtlen, A. Reale |
| title_short | Adalat |
| title_sort | adalat a comprehensive review |
| title_sub | A Comprehensive Review |
| topic | Cardiology Nifedipin (DE-588)4042297-5 gnd Pharmakotherapie (DE-588)4076066-2 gnd Geschichte (DE-588)4020517-4 gnd |
| topic_facet | Cardiology Nifedipin Pharmakotherapie Geschichte Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-642-85498-9 |
| work_keys_str_mv | AT lichtlenpr adalatacomprehensivereview AT realea adalatacomprehensivereview |